Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYH2085 Safety and PK in Healthy Chinese Participants
NCT07412353Phase 1Recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jan 2026
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in solid tumor comparing SYH2085 SAD experimental group with Placebo SAD group (2 arms). Primary endpoint: Number of adverse events at 22 days. Started Jan 2026; status: recruiting.
02
Drugs
SYH2085
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07412353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07412353.